ARCHIVES

STI-571 Effects Are Lasting Against GI Stromal Tumors

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Scrutiny of caBIG Exposes Conflicts, Bonanza For Contractors

March 18, 2011

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

Scientific Misconduct: HHS To Change Role Of ORI In Response To Council Report

December 3, 1999

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

PRI, Fending Off More Giants, Reportedly wins New operations. Support contract at Frederick

July 10, 1987

Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research

September 13, 1996